



Food and Drug Administration
Silver Spring, MD 20993

Devin Watkins, Attorney
Sam Kazman, General Counsel
Competitive Enterprise Institute
1310 L Street NW, 7th Floor
Washington, DC 20005
devin.watkins@cei.org;
sam.kazman@cei.org

July 6, 2022

Sent electronically

RE: Request for Correction regarding Voluntary Sodium Reduction Goals: Target Mean and Upper Bound Concentrations for Sodium in Commercially Processed, Packaged, and Prepared Foods (86 FR 57156) (Oct. 14, 2021)

Mr. Watkins and Mr. Kazman,

This letter is an interim response to your November 9, 2021, request for correction pursuant to Section 515(a) of the Treasury and General Government Appropriations Act for Fiscal Year 2001, Pub.L. No.106-554, 114 Stat. 2763A-153 (2000) (the Federal Data Quality Act).

This letter also acknowledges receipt of your June 6, 2022, correspondence to Associate Commissioner for Policy, Lauren Roth, in which you asked that the article *Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomized, controlled trial*, The Lancet, Vol. 399, Issue 10333, 2022, Pages 1391-1400 (April 9, 2022) Justin A. Ezekowitz et al., be included in your original petition.

Given that the subject of your Information Quality Request for Correction is based on information disseminated on October 14, 2021 (86 FR 57156), which is before this article was published, it will not be considered part of the IQA Request for Correction. However, FDA appreciates the additional information and would suggest that you submit it to the docket for this final guidance so that it can be considered at an appropriate time.

We anticipate providing you with a response to your November 9, 2021, Request for Correction within 60 days, either by issuing a decision or by providing you with an estimated decision date.

Sincerely,

A handwritten signature in cursive script, appearing to read "L. Lenkel".

Laurie Lenkel
FDA Office of the Ombudsman